Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome

Journal of Clinical Lipidology

Volumn 4, Issue 6, 2010, Pages 515-521

  Bays, Harold E ^a   Shah, Arvind ^b   Lin, Jianxin ^b   McCrary Sisk, Christine ^b   Paolini, John F ^b   MacCubbin, Darbie ^b  

^a LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cardiovascular risk; Dyslipidemia; Flushing; Glucose; High blood pressure; Laropiprant; Metabolic syndrome; Niacin

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTILIPEMIC AGENT; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CREATINE KINASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAROPIPRANT PLUS NICOTINIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; DYSLIPIDEMIA; EXTENDED DRUG RELEASE; FEMALE; FLUSHING; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MYOPATHY; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TABLET; THERAPY EFFECT; TOXIC HEPATITIS; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPOLIPIDEMIC AGENTS; INDOLES; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NIACIN;

EID: 78649641649     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2010.08.020     Document Type: Article

References (16)

1. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
2. J. Vakkilainen, G. Steiner, J.C. Ansquer, H. Perttunen-No, and M.R. Taskinen Fenofibrate lowers plasma triglycerides and increases LDL particle diameter in subjects with type 2 diabetes Diabetes Care 25 2002 627 628
3. K. Cheng, T.J. Wu, and K.K. Wu Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans Proc Natl Acad Sci U S A 103 2006 6682 6687
4. C.F. Sturino, G. O'Neill, and N. Lachance Discovery of a Potent and Selective Prostaglandin D(2) Receptor Antagonist, [(3R)-4-(4-Chloro-benzyl)-7- fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic Acid (MK-0524) J Med Chem 50 2007 794 806
5. J.F. Paolini, Y.B. Mitchel, and R. Reyes Effects of laropiprant on nicotinic acid-induced flushing in dyslipidemic patients Am J Cardiol 101 2008 625 630
6. D. Maccubbin, H.E. Bays, and A.G. Olsson Lipid-modifying efficacy and tolerability of extended release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia Int J Clin Pract 62 2008 1959 1970
7. H. Bays Safety of niacin and simvastatin combination therapy Am J Cardiol 101 2008 3B 8B
8. S.M. Grundy, J.I. Cleeman, C.N.B. Merz for the Coordinating Committee of the National Cholesterol Education Program NCEP Report. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines Circulation 110 2004 227 239 (Pubitemid 38924592)
9. H.E. Bays, and D.J. Rader Does nicotinic acid (niacin) lower blood pressure? Int J Clin Pract 63 2009 151 159
10. J.R. Guyton, and H.E. Bays Safety considerations with niacin therapy Am J Cardiol 99 suppl 2007 22C 31C
11. F. Tat, G.L. Vega, and S.M. Grundy Effects of crystalline nicotinic acid-induced hepatic dysfunction of serum low-density lipoprotein cholesterol and lecithin cholesteryl acyl transferase Am J Cardiol 81 1998 805 807
12. J.I. Rader, R.J. Calvert, and J.N. Hathcock Hepatic toxicity of unmodified and time-release preparations of niacin Am J Med 92 1992 77 81
13. S.M. Grundy, G.L. Vega, and M.E. McGovern Efficacy, safety, and tolerability of once-daily niacin for the treatment of dysplipidemia associated with type 2 diabetes - results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial Arch Intern Med 162 2002 1568 1576
14. M.B. Elam, D.B. Hunninghake, and K.B. Davis Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease JAMA 284 2000 1263 1270
15. H.E. Bays "Sick fat," metabolic disease, and atherosclerosis Am J Med 122 1 Suppl 2009 S26 S37
16. P.L. Canner, C.D. Furberg, M.L. Terrin, and M.E. McGovern Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project) Am J Cardiol 95 2005 254 257